Exchange: PNK Industry: Medical Devices
1.26% $1.610
America/New_York / 3 mai 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 49.89 mill |
EPS: | -1.060 |
P/E: | -1.520 |
Earnings Date: | Jun 26, 2024 |
SharesOutstanding: | 30.99 mill |
Avg Daily Volume: | 0.195 mill |
RATING 2024-05-03 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.520 | sector: PE -11.58 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -1.520 | industry: PE -6.92 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.207 (-87.13%) $-1.403 |
Date: 2024-05-04 |
Expected Trading Range (DAY) |
---|
$ 1.451 - 1.769 ( +/- 9.88%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-08 | Diperna Paul | Buy | 100 000 | Option to purchase common stock |
2024-04-08 | Schmid Kevin | Buy | 50 000 | Option to purchase common stock |
2024-03-31 | Frank Morgan C. | Buy | 7 500 | Option to purchase common stock |
2024-03-31 | Frank Morgan C. | Buy | 1 875 | Option to purchase common stock |
2024-03-29 | Felsher Steven G | Buy | 750 | Common Stock |
INSIDER POWER |
---|
88.67 |
Last 99 transactions |
Buy: 2 591 808 | Sell: 175 000 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.610 (1.26% ) |
Volume | 0.0319 mill |
Avg. Vol. | 0.195 mill |
% of Avg. Vol | 16.39 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Modular Medical, Inc., a development stage medical device company, focuses on the design, development, and commercialization of insulin pumps using technology to enhance pump adoption in the diabetes marketplace. The company is headquartered in San Diego, California.